Zymeworks (Zymeworks) Long-Term Capital Lease Obligation : $21.07 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zymeworks Long-Term Capital Lease Obligation?

Zymeworks's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $21.07 Mil.

Zymeworks's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($22.53 Mil) to Dec. 2023 ($22.46 Mil) and declined from Dec. 2023 ($22.46 Mil) to Mar. 2024 ($21.07 Mil).

Zymeworks's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($31.02 Mil) to Dec. 2022 ($24.79 Mil) and declined from Dec. 2022 ($24.79 Mil) to Dec. 2023 ($22.46 Mil).

Zymeworks Long-Term Capital Lease Obligation Historical Data

The historical data trend for Zymeworks's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Long-Term Capital Lease Obligation Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.65

5.93

31.02

24.79

22.46

Zymeworks Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															23.97	23.61	22.53	22.46	21.07

Zymeworks (NAS:ZYME) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Zymeworks Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zymeworks's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (Zymeworks) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ZA8:Germany

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Executives

Paul Andrew Moore	officer: Chief Scientific Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle	officer: SVP & Chief Financial Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith	director, officer: Chair & CEO	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy	director	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael	director	108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas	officer: President & COO	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Troy Cox	director	C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton	director
Kelvin Neu	director	860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson	officer: Chief Medical Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4